An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products

The purpose of this study was to predict in vivo performance of three oral products of Etoricoxib (Arcoxia(®) as reference and two generic formulations in development) by conducting in vivo predictive dissolution with GIS (Gastro Intestinal Simulator) and computational analysis. Those predictions we...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Alvarez, Isabel, Bermejo, Marival, Tsume, Yasuhiro, Ruiz-Picazo, Alejandro, Gonzalez-Alvarez, Marta, Hens, Bart, Garcia-Arieta, Alfredo, Amidon, Greg E., Amidon, Gordon L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067797/
https://www.ncbi.nlm.nih.gov/pubmed/33917118
http://dx.doi.org/10.3390/pharmaceutics13040507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067797/
https://www.ncbi.nlm.nih.gov/pubmed/33917118
http://dx.doi.org/10.3390/pharmaceutics13040507

Ejemplares similares